Targeting the Isoprenoid Biosynthetic Pathway in Multiple Myeloma.

ABSTRACT: Multiple myeloma (MM) is a plasma cell malignancy for which there is currently no cure. While treatment options for MM have expanded over the last two decades, all patients will eventually become resistant to current therapies. Thus, there is an urgent need for novel therapeutic strategies to treat MM. The isoprenoid biosynthetic pathway (IBP) is responsible for the post-translational modification of proteins belonging to the Ras small GTPase superfamily, such as Ras, Rho and Rab family members. Given the important roles these GTPase proteins play in various cellular processes, there is significant interest in the development of inhibitors that disturb their prenylation and consequently their activity in MM cells. Numerous preclinical studies have demonstrated that IBP inhibitors have anti

SUBMITTER: Haney SL 

PROVIDER: S-EPMC9820492 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature